Home > Insider Trading > Filing (0001387131-16-004331)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1173281	Ohr Pharmaceutical Inc	OHRP	Pharmaceutical Preparations (2834)	465622433

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1630109	Scott Jason Slakter	C/O Ohr Pharmaceutical Inc. 800 Third Ave., 11Th Floor New York NY 10022	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock, Par Value $0.0001 Per Share	Acquisiton	2016-02-22	100	$3.21	865,854	No	4	P	Direct
Common Stock, Par Value $0.0001 Per Share	Acquisiton	2016-02-22	300	$3.15	866,154	No	4	P	Direct
Common Stock, Par Value $0.0001 Per Share	Acquisiton	2016-02-22	100	$3.14	866,254	No	4	P	Direct
Common Stock, Par Value $0.0001 Per Share	Acquisiton	2016-02-22	200	$3.13	866,454	No	4	P	Direct
Common Stock, Par Value $0.0001 Per Share	Acquisiton	2016-02-22	700	$3.12	867,154	No	4	P	Direct
Common Stock, Par Value $0.0001 Per Share	Acquisiton	2016-02-22	3,550	$3.11	870,704	No	4	P	Direct
Common Stock, Par Value $0.0001 Per Share	Acquisiton	2016-02-22	100	$3.10	870,804	No	4	P	Direct
Common Stock, Par Value $0.0001 Per Share	Acquisiton	2016-02-22	200	$3.09	871,004	No	4	P	Direct
Common Stock, Par Value $0.0001 Per Share	Acquisiton	2016-02-22	500	$3.08	871,504	No	4	P	Direct
Common Stock, Par Value $0.0001 Per Share	Acquisiton	2016-02-22	300	$3.07	871,804	No	4	P	Direct
Common Stock, Par Value $0.0001 Per Share	Acquisiton	2016-02-22	200	$3.06	872,004	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock, Par Value $0.0001 Per Share	697,865	Indirect	BY SKS Ocular I LLC

Footnotes

SKS Ocular I LLC directly owns the shares of Common Stock. On May 30, 2014, the Issuer completed an ophthalmology assets acquisition of SKS Ocular LLC and SKS Ocular I LLC. Pursuant to the acquisition agreement, among other things, SKS Ocular I LLC is eligible to receive additional shares of Common Stock in three contingent milestone payments. Milestone 1 has been met and on December 15, 2015, the Issuer issued 497,859 shares of Common Stock to SKS Ocular I LLC. The Reporting Person has investment and voting power with respect to the Common Stock held by SKS Ocular 1 LLC. Therefore, the Reporting Person may be deemed to beneficially own the shares of Common Stock beneficially owned by SKS Ocular 1 LLC. The Reporting Person disclaims any beneficial ownership of the Common Stock directly owed by SKS Ocular I LLC except to the extent of his pecuniary interest therein.